It is the study for analysis of patients of carcinoma esophagus and gastroesophageal junction who have received chemotherapy before.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Patients of ca esophagus and gastroesophageal junction who have received docetaxel, platinum and 5-Fluorouracil as induction therapy
- Registration Number
- CTRI/2014/08/004839
- Lead Sponsor
- ot applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 31
Inclusion Criteria
We will include patients who have received DCF induction chemotherapy for potentially resectable esophageal and GE junction carcinoma, from January 2010 to May 2014, whose data has been prospectively entered in a database that has been maintained in the medical oncology department at Tata Memorial Hospital.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the pathologic complete remission rate of DCF induction chemotherapy in locally advanced resectable or borderline resectable CA of esophagus or GE junction. <br/ ><br>Timepoint: Post Surgery
- Secondary Outcome Measures
Name Time Method 1.Toxicity <br/ ><br>2.Response rate <br/ ><br>3.Resection rate <br/ ><br>4.R0 resection rate <br/ ><br>5.Overall survival <br/ ><br>6.Progression-free survival <br/ ><br>7.Evaluate factors that affect survival. <br/ ><br>Timepoint: 1. Every 3 weeks on chemotherapy for Toxicity <br/ ><br>2. R0 resection rate: at the time of Surgery <br/ ><br>3. For progression free survival & Overall survival: Every 3 months for 3 years. <br/ ><br>4. Response Rate:Following chemotherapy 1 to 2 weeks after last cycle of induction chemotherapy.